## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 3.0% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1018.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)**
- Source: Insider Monkey | 20251221T180815 | Bullish | Relevance: 100%
- Eli Lilly and Company (LLY) announced updated results from its Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for advanced or metastatic breast cancer, showing continued clinical benefits. The company also revealed plans to invest over $6 billion in a new manufacturing facility in Huntsville, Alabama, to produce synthetic and peptide medicines, including forforglipron. Eli Lilly is recognized as a strong investment, though the article suggests even greater potential in certain AI stocks.

**2. Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)**
- Source: Yahoo Finance | 20251221T154727 | Bullish | Relevance: 100%
- Eli Lilly and Company released updated Phase 3 EMBER-3 study results for Inluriyo (imlunestrant), an oral estrogen receptor antagonist, showing continued clinical benefits for patients with ER+, HER2- advanced or metastatic breast cancer. The data supports Inluriyo's role both as monotherapy and in combination with abemaciclib, demonstrating durable benefits regardless of ESR1 mutation status. The company also announced plans for a new $6 billion manufacturing facility in Huntsville, Alabama, which will produce small molecule synthetic and peptide medicines, including orforglipron for obesity.

**3. Abivax jumps on media reports of Eli Lilly takeover bid**
- Source: TradingView â€” Track All Markets | 20251222T090959 | Somewhat-Bullish | Relevance: 74%
- Abivax shares (ABVX) surged 8% following unconfirmed media reports of a potential takeover bid by Eli Lilly (LLY). A French outlet suggested Eli Lilly met with France's Treasury to discuss regulatory approval for acquiring Abivax. While Abivax declined to comment on market rumors, speculation surrounding a deal has intensified, with one trader suggesting a meeting with the Treasury indicates an agreed-upon price in principle.

**4. Fluent Financial LLC Makes New Investment in Biogen Inc. $BIIB**
- Source: MarketBeat | 20251221T120852 | Somewhat-Bullish | Relevance: 74%
- Fluent Financial LLC has acquired a new stake in Biogen Inc. (NASDAQ:BIIB), purchasing 25,543 shares valued at approximately $3.58 million, making it their 23rd largest position. Biogen recently exceeded Q3 earnings and revenue expectations and has set a positive FY2025 guidance. The stock currently holds a consensus "Hold" rating from analysts with an average price target of $183.08.

**5. CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer**
- Source: Benzinga | 20251222T181013 | Somewhat-Bullish | Relevance: 74%
- CRISPR Therapeutics provided an update on zugocaptagene geleucel (zugo-cel), an investigational allogeneic CAR T therapy. The therapy showed a 90% overall response rate and 70% complete response rate in patients with relapsed/refractory large B-cell lymphoma (LBCL), with encouraging preliminary data also seen in autoimmune rheumatologic diseases. The company is collaborating with Eli Lilly and Co. to further develop zugo-cel in aggressive B-cell lymphomas.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.49M) |
| Sells | 28 ($18559.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.0% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $18559M sold (28 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.99 indicates undervaluation relative to growth. Forward P/E 33.1x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (4 raises, avg +12%). Insider selling cluster ($18559.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $965.0B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.99 |
| Forward P/E | 33.1 |
| Current P/E | 45.5 |
| YoY Growth | 37.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.9% to 3.0% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.0pp (needs >3.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Outperforming sector by 3.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.91), momentum weakening. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.95% (CS: 89) | Neutral |
| RSI_14 | 64.7 | Neutral |
| MACD Histogram | -0.91 | Bearish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.120x | Above |
| vs SMA200 | 1.314x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1076.15
- **Stop Loss:** $1018.27 (5.4% risk)
- **Target:** $1134.03 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $21,523.00
- **Portfolio %:** 21.52%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*